Enfortumab Vedotin Structural Formula (Image 01)
The provided text is not-available.*
Padcev Injection, Powder, Lyophilized, For Solution
Product Images NDC 51144-030
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Padcev (NDC 51144-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Seagen Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Padcev (enfortumab Vedotin-ejfv) For Injection 20 mg/vial Label (Image 02)
Each vial of PADCEV contains 20 mg of enfortumab for intravenous infusion only. It is recommended to store the vial refrigerated and not to shake it before use. The vial also contains histidine and trademarks are jointly owned by Sezgn and PADCEV. The potency standard is not regulated by the US. Other information on this document is not legible.*
Padcev (enfortumab Vedotin-ejfv) For Injection 30 mg/vial Label (Image 03)
PADCEV is a cytotoxic agent that is administered through intravenous infusion after reconstitution and dilution. Each single-dose vial contains 30 mg of enfortumab vedotin and should be discarded after use. A caution against cytotoxicity is issued on the label because the medication can be harmful. Furthermore, there is a warning that the medication is destroyed when frozen, so storing it between 36°F and 46°F (2°C to 8°C) is advised. Agensys, Inc., and Seagen Inc. own PADCEV and the PADCEV device trademarks.*
Image 04
Image 05
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
